Crystallization and preliminary crystal structure of the complex of 17β-hydroxysteroid dehydrogenase with a dual-site inhibitor

Journal of Steroid Biochemistry and Molecular Biology

Volumn 70, Issue 4-6, 1999, Pages 229-235

  Zhu, Dao Wei ^a   Campbell, Robert ^a   Labrie, Fernand ^a   Lin, Sheng Xiang ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Crystallization; Estradiol; Inhibitor; Protein; Structure

Indexed keywords

TESTOSTERONE 17BETA DEHYDROGENASE;

ARTICLE; CATALYSIS; CRYSTAL; CRYSTAL STRUCTURE; CRYSTALLIZATION; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME STRUCTURE; ENZYME SUBSTRATE COMPLEX; ESTROGEN SYNTHESIS; X RAY DIFFRACTION;

APOENZYMES; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; ESTRADIOL; ESTRADIOL DEHYDROGENASES; ESTROGEN ANTAGONISTS; ESTRONE; FEMALE; HUMANS; OVARY;

EID: 0032722866     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(99)00111-9     Document Type: Article

References (28)

1. Ghosh D., Pletnev V., Zhu D.-W., Wawrzak Z., Duax W.-L., Pangborn W., Labrie F., Lin S.-X. Structure of human 17β-hydroxysteroid dehydrogenase at 2.20 Å resolution. Structure. 3:1995;503-513.
2. β-estradiol. Nature Struct. Biol. 3:1996;665-668.
3. Labrie C., Martel G., Dufour J.M., Levesque G., Merand Y., Labrie F. Novel compounds inhibit estrogen formation and action. Cancer Res. 52:1992;610-615.
4. Poutanen M., Isomaa V., Lehto V.P., Vihko R. Immunological analysis of 17 beta-hydroxysteroid dehydrogenase in benign and malignant human breast tissue. Int. J. Cancer. 50:1992;386-390.
5. Luu-The V., Labrie C., Zhao H.F., Couët L., Lachance Y., Simard J., Leblanc G., Côté J., Bérubé D., Gagné R., Labrie F. Characterization of cDNAs for human estradiol 17 beta-dehydrognase and assignement of the gene to chromosome 17: evidence of two mRNA species with distinct 5′-termini in human placenta. Mol. Endocrinol. 3:1989;1301-1309.
6. Luu-The V., Labrie C., Simard L., Lachance Y., Zhao H.-F., Couet J., Leblanc G., Labrie F. Structure of two in tandem human 17β-hydroxysteroid dehydrogenase genes. Mol. Endocrinol. 4:1990;268-275.
7. Labrie F., Luu-The V., Lin S.-X., Labrie C., Simard J., Breton R., Bélanger A. The key role of 17β-hydroxysteroid dehydrogenases in sex steroid biology. Steroids. 62:1997;148-158.
8. β-dehydrogenase. Biochem. Biophys. Res. Commun. 180:1991;1057-1063.
9. Lawate S.S., Covey D.F. Trifluoroacetic alcohols as affinity labels: Inactivation of estradiol dehydrogenase by a trifluoromethylacetilenic secoestradiol. J. Med. Chem. 33:1990;2319-2321.
10. Auchus R.J., Palmer J.O., Carrell H.L., Covey D.F. Preparation of 14,15-secoestra-1,3,5(10)-trien-15-ynes, inhibitors of estradiol dehydrogenase. Steroids. 53:1989;77-97.
11. Murdock G.L., Chin C.C., Warren J.C. Human placental estradiol 17β-dehydrogenase: sequence of a histidine-bearing peptide in the catalytic region. Biochemistry. 25:1986;641-646.
12. Inano H., Tamaoki B. Affinity labeling of arginyl residues at the catalytic region of estradiol 17β-dehydrogenase from human placenta by 16-oxoestrone. Eur. J. Biochem. 129:1983;691-695.
13. Thomas J.L., LaRochelle M.C., Covey D.F., Strickler R.C. Inactivation of human placental 17β, 20α-hydroxysteroid dehydrogenase by 16-methylene estrone, an affinity alkylator enzymatically generated from 16-methylene estradiol-17 beta. J. Biol. Chem. 258:1983;11500-11504.
14. Tremblay M.R., Augers S., Poirier D. Synthesis of 16-(bromoalkyl)-estradiols having inhibitory effect on human placental estradiol 17β-hydroxysteroid dehydrogenase (17β-HSD type 1). Bioorg. Med. Chem. 3:1995;505-523.
15. Pelletier J.D., Labrie F., Poirier D. N-butyl, N-methyl, 11-[3′,17′ beta-(dihydroxy)-1′,3′,5′(10′)-estratrien- 16′alpha-yl]-9(R/S)-bromo undecanamide: synthesis and 17 beta-HSD inhibiting, estrogenic and antiestrogenic activities. Steroids. 59:1994;536-547.
16. Pelletier J.D., Poirier D. Synthesis and evaluation of estradiol derivatives with 16 alpha-(bromoalkylamide), 16 alpha-(bromoalkyl) or 16 alpha-(bromoalkynyl) side chain as inhibitors of 17 beta-hydroxysteroid dehydrogenase type 1 without estrogenic activity. Bioorg. Med. Chem. 4:1996;1617-1628.
17. Lévesque C., Mérand Y., Dufour J.M., Labrie C., Labrie F. Synthesis and biological activity of new halo-steroidal antiestrogens. J. Med. Chem. 34:1991;1624-1630.
18. Zhu D.-W., Lee X., Breton R., Ghosh D., Pangborn W., Duax W.L., Lin S.-X. Crystallization and preliminary X-ray diffraction analysis of the complex of human placental 17β-hydroxysteroid dehydrogenase with NADP+. J. Mol. Biol. 234:1993;242-244.
19. Breton R., et al. The structure of a complex of human 17β-hydroxysteroid dehydrogenase with estradiol and NADP+ identifies two principal targets for the design of inhibitors. Structure. 4:1996;905-915.
20. Lin S.-X., Yang F., Jin J.-Z., Breton R., Zhu D.-W., Luu-The V., Labrie F. Subunit identity of the dimeric 17β-hydroxysteroid dehydrogenase from human placenta. J. Biol. Chem. 267:1992;16182-16187.
21. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
22. Zhu D.-W., Lee X., Labrie F., Lin S.-X. Crystal Growth of Human Estrogenic 17β-hydroxysteroid Dehydrogenase. Acta Crystallogr. D50:1994;550-555.
23. Zhu D.-W., Azzi A., Rehse P., Lin S.-X. The crystallogenesis of a human estradiol dehydrogenase-substrate complex. J. Cryst. Growth. 168:1996;275-279.
24. Zhu D.-W., Jin J.-Z., Lin S.-X. Human 17β-hydroxysteroid dehydrogenase: optical properties of its complex with NADP. J. Steroid Biochem. Molec. Biol. 52:1995;77-81.
25. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Carter C.W.J., Sweet R.M. Methods in Enzymology. 1996;276 Academic Press.
26. Singh A., Purohit A., Duncan L.J., Mokbel K., Ghilchik M.W., Reed M.J. Control of aromatase activity in breast tumours: the role of the immune system. J. Steroid Biochem. Molec. Biol. 61:1997;185-192.
27. Johannessen D.C., Engan T., Di Salle E., Zurlo M.G., Paolini J., Ornati G., Piscitelli G., Kvinnsland S., Lonning P.E. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin. Cancer Res. 3:1997;1101-1108.
28. Poulin R., Labrie F. Stimulation of cell proliferation and estrogenic response by adrenal C19-Δ5-steroids in ZR-75-1 human breast cancer cell line. Cancer Research. 46:1986;4933-4937.